Physician profile
Marek Hirsch
NPI 1295167385
$1,766.38
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2021: $496 · 2022: $227 · 2023: $580 · 2024: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $695.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $947.89 | 2019-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Livanova USA, INC. | $269.65 | 2021 | |
| Abbvie INC. | $247.51 | 2023-2024 | |
| Allergan, INC. | $110.01 | 2019 | |
| Edwards Lifesciences Corporation | $75.80 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.87 | 2024 | Caplyta |
| Lundbeck LLC | $23.75 | 2024 | Rexulti |
| Neos Therapeutics, Lp | $19.76 | 2023 | Adzenys Xr-Odt |
| Vanda Pharmaceuticals INC. | $18.35 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.58 | 2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $13.21 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marek Hirsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.